- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05270668
간질성 폐질환과 관련된 전신 경화증(SSc-ILD) 대상자를 대상으로 한 PRA023의 2상 안전성 및 효능 연구 (ATHENA-SSc-ILD)
간질성 폐 질환과 관련된 전신 경화증(SSc-ILD) 대상자에서 PRA023의 효능 및 안전성을 평가하기 위한 이중 맹검, 무작위, 위약 대조 연구
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
연구 개요
상태
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Gelderland
-
Nijmegen, Gelderland, 네덜란드, 6500 HB
- Radboud University Medical Center ( Site 4650)
-
-
-
-
-
Oslo, 노르웨이, 0372
- Oslo Universitetssykehus HF. Rikshospitalet ( Site 4350)
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79106
- Universitaetsklinikum Freiburg ( Site 4152)
-
-
Hesse
-
Bad Nauheim, Hesse, 독일, 61231
- Kerckhoff-Klinik-Forschungs-GmbH ( Site 4153)
-
-
Mecklenburg-Vorpommern
-
Hohenfelde B Bad Doberan, Mecklenburg-Vorpommern, 독일, 18209
- Rheumazentrum am Krankenhaus Bad Doberan ( Site 4150)
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, 독일, 50937
- Universitaetsklinikum Koeln ( Site 4151)
-
-
-
-
Jalisco
-
Guadalajara, Jalisco, 멕시코, 44670
- PanAmerican Clinical Research - Guadalajara ( Site 4900)
-
-
Mexico City
-
Mexico City, Mexico City, 멕시코, 31000
- Centro de Investigación y Tratamiento Reumatológico S.C ( Site 4902)
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85054
- Mayo Clinic - Scottsdale ( Site 4014)
-
-
California
-
Los Angeles, California, 미국, 90045
- Pacific Arthritis Care Center ( Site 4008)
-
Los Angeles, California, 미국, 90048
- Cedars Sinai Medical Center ( Site 4010)
-
Los Angeles, California, 미국, 90095-1670
- UCLA School of Medicine ( Site 4006)
-
Palo Alto, California, 미국, 94304
- Stanford Health Care ( Site 4009)
-
-
Colorado
-
Denver, Colorado, 미국, 80206
- National Jewish Health Medical Center ( Site 4015)
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06519
- Yale University ( Site 4017)
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20007
- MedStar Georgetown University Hospital ( Site 4005)
-
-
Maryland
-
Baltimore, Maryland, 미국, 21224
- Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018)
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital ( Site 4003)
-
Boston, Massachusetts, 미국, 02118
- Boston University School of Medicine ( Site 4021)
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Hospital ( Site 4001)
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08901
- Rutgers Robert Wood Johnson Medical School ( Site 4013)
-
-
New York
-
New York, New York, 미국, 10021
- Hospital For Special Surgery ( Site 4020)
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic Foundation ( Site 4019)
-
Toledo, Ohio, 미국, 43614
- University of Toledo Medical Center ( Site 4002)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburgh Medical Center ( Site 4016)
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Medical University of South Carolina - PPDS ( Site 4004)
-
-
Texas
-
Houston, Texas, 미국, 77030
- UT Physicians Rheumatology ( Site 4007)
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- Froedtert and Medical College of Wisconsin ( Site 4012)
-
-
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, 벨기에, 9000
- UZ Gent ( Site 4401)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, 벨기에, 3000
- UZ Leuven ( Site 4402)
-
-
Wallonne, Region
-
Liège, Wallonne, Region, 벨기에, 4000
- CHU de Liege ( Site 4400)
-
-
-
-
-
Geneva, 스위스, 1211
- Hopitaux Universitaires de Geneve HUG ( Site 4503)
-
Zurich, 스위스, 8091
- Universitaetsspital Zuerich ( Site 4500)
-
-
Canton of Bern
-
Bern, Canton of Bern, 스위스, 3010
- Inselspital Bern ( Site 4502)
-
-
Canton of St. Gallen
-
Sankt Gallen, Canton of St. Gallen, 스위스, 9007
- Kantonsspital St. Gallen ( Site 4501)
-
-
-
-
-
Barcelona, 스페인, 08035
- Hospital Universitario Vall d'Hebron - PPDS ( Site 4107)
-
Barcelona, 스페인, 08041
- Hospital Santa Creu i Sant Pau ( Site 4102)
-
Madrid, 스페인, 28034
- Hospital Universitario Ramon y Cajal ( Site 4101)
-
Málaga, 스페인, 29009
- Hospital Regional Universitario de Malaga ( Site 4104)
-
Valencia, 스페인, 46017
- Hospital Universitario Doctor Peset ( Site 4103)
-
Zaragoza, 스페인, 50009
- Hospital Clinico Universitario Lozano Blesa ( Site 4100)
-
-
Catalonia
-
Barcelona, Catalonia, 스페인, 08036
- HOSPITAL CLÍNIC DE BARCELONA ( Site 4105)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, 스페인, 28041
- Hospital Universitario 12 de Octubre ( Site 4106)
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, 스페인, 33011
- Hospital Central de Asturias ( Site 4109)
-
-
-
-
Buenos Aires
-
CABA, Buenos Aires, 아르헨티나, C1426ABP
- Consultorios Médicos Dr. Doreski ( Site 4800)
-
Munro, Buenos Aires, 아르헨티나, 1605
- Clínica Privada Independencia ( Site 4802)
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, 아르헨티나, 5800
- Centro de Investigación Instituto Médico Río Cuarto ( Site 4801)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, 아르헨티나, S2000CEJ
- Instituto Medico de la Fundacion Estudios Clinicos ( Site 4803)
-
-
-
-
-
Leeds, 영국, LS7 4SA
- Chapel Allerton Hospital ( Site 4551)
-
-
London, City of
-
London, London, City of, 영국, NW3 2QG
- Royal Free Hospital ( Site 4550)
-
-
-
-
-
Kyiv, 우크라이나, 02091
- Medical Center OK!Clinic+LLC International Institute of Clinical Research ( Site 4753)
-
Kyiv, 우크라이나, 2081
- Institute of Rheumatology LLC ( Site 4752)
-
-
Kyivska Oblast
-
Kyiv, Kyivska Oblast, 우크라이나, 02125
- Kyiv City Clinical Hospital # 3 ( Site 4754)
-
-
Ternopil Oblast
-
Ternopil, Ternopil Oblast, 우크라이나, 46002
- ME "Ternopil Regional Clinical Hospital of Ternopil Regional Council" ( Site 4750)
-
-
Vinnytsia Oblast
-
Vinnytsia, Vinnytsia Oblast, 우크라이나, 21018
- Vinnytsia Nat Med University n.a.M.Pyrogov,City Clinical Hospital #1 ( Site 4751)
-
-
-
-
-
Haifa, 이스라엘, 3109601
- Rambam Medical Center ( Site 4601)
-
Kfar Saba, 이스라엘, 4428164
- Meir Medical Center. ( Site 4604)
-
Nahariya, 이스라엘, 2210001
- Galilee Medical Center ( Site 4602)
-
Petach Tikvah, 이스라엘, 49100
- Rabin Medical Center ( Site 4603)
-
Ramat Gan, 이스라엘, 5265601
- Sheba Medical Center ( Site 4605)
-
Tel Aviv, 이스라엘, 6423906
- Tel Aviv Sourasky Medical Center ( Site 4606)
-
-
-
-
-
Florence, 이탈리아, 50141
- Azienda Ospedaliera Universitaria Careggi ( Site 4301)
-
Genova, 이탈리아, 16132
- Ospedale Policlinico San Martino ( Site 4305)
-
Milan, 이탈리아, 20122
- IRCCS Osp. Maggiore Policlinico ( Site 4306)
-
Milan, 이탈리아, 20132
- Ospedale San Raffaele di Milano ( Site 4307)
-
Pavia, 이탈리아, 27100
- Fondazione IRCCS Policlinico San Matteo ( Site 4303)
-
Reggio Emilia, 이탈리아, 42123
- Arcispedale Santa Maria Nuova ( Site 4300)
-
Roma, 이탈리아, 00161
- Azienda Policlinico Umberto I ( Site 4302)
-
-
Piedmont
-
Turin, Piedmont, 이탈리아, 10126
- A.O.U. Citta della Salute e della Scienza di Torino ( Site 4304)
-
-
-
-
Araucania
-
Temuco, Araucania, 칠레, 4780000
- Centro de especialidades médicas Vanguardia ( Site 4850)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, 칠레, 8320000
- BIOCINETIC Ltda ( Site 4854)
-
Santiago, Region M. de Santiago, 칠레, 8330034
- Centro de Investigacion Clinica UC CICUC ( Site 4855)
-
Santiago, Region M. de Santiago, 칠레, 8420383
- Centro Internacional de Estudios Clinicos CIEC ( Site 4851)
-
Vitacura, Region M. de Santiago, 칠레, 7640881
- Clinica Dermacross ( Site 4853)
-
-
Valparaiso
-
Viña del Mar, Valparaiso, 칠레, 2520598
- ONCOCENTRO APYS ( Site 4852)
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 1W9
- University Of Alberta Hospital ( Site 4702)
-
-
Ontario
-
London, Ontario, 캐나다, N6A 4V2
- St. Joseph's Health Care London ( Site 4701)
-
Toronto, Ontario, 캐나다, M5T 3L9
- Mount Sinai Hospital [Toronto, Canada] ( Site 4700)
-
-
-
-
-
Lima, 페루, 15023
- Instituto de Ginecologia y Reproduccion ( Site 4952)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, 폴란드, 61-293
- Twoja Przychodnia Poznanskie Centrum Medyczne ( Site 4452)
-
Warszawa, Greater Poland Voivodeship, 폴란드, 02-637
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im.Prof. El. Reicher-ul.Spartanska 1 ( Site
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-168
- Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy ( Site 4454)
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, 폴란드, 52-416
- Centrum Medyczne Oporow ( Site 4455)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, 폴란드, 02-691
- Centrum Medyczne Reuma Park NZOZ ( Site 4450)
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, 폴란드, 15-276
- Uniwersytecki Szpital Kliniczny w Bialymstoku - Marii Sklodowskiej-Curie 24A ( Site 4451)
-
-
Silesian Voivodeship
-
Bytom, Silesian Voivodeship, 폴란드, 41-902
- Szpital Specjalistyczny nr 1 w Bytomiu ( Site 4453)
-
-
-
-
-
Paris, 프랑스, 75679
- Hopital Cochin ( Site 4203)
-
-
Nord
-
Bordeaux, Nord, 프랑스, 33076
- CHU de Bordeaux. Hopital Pellegrin ( Site 4202)
-
Lille, Nord, 프랑스, 59000
- Hôpital Claude Huriez ( Site 4200)
-
-
-
-
-
Budapest, 헝가리, 1023
- Budai Irgalmasrendi Korhaz ( Site 4252)
-
Budapest, 헝가리, 1097
- Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet ( Site 4253)
-
Debrecen, 헝가리, 4032
- Debreceni Egyetem Klinikai Kozpont ( Site 4251)
-
-
Baranya
-
Pécs, Baranya, 헝가리, 7632
- Pecsi Tudomanyegyetem AOK ( Site 4250)
-
-
-
-
South Australia
-
Adelaide, South Australia, 호주, 5000
- Royal Adelaide Hospital ( Site 4050)
-
-
Victoria
-
Melbourne, Victoria, 호주, 3065
- St Vincents Hospital Melbourne ( Site 4051)
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Has confirmed diagnosis of systemic sclerosis with onset of disease ≤ 5 years ago.
- Has diffuse cutaneous scleroderma
- Has systemic sclerosis related interstitial lung disease confirmed by HRCT
- FVC ≥ 45% of predicted normal
- Diffusing capacity of lung for carbon monoxide (DLCO)≥ 45% of predicted normal
- If on background therapy, meets stable dosing requirements for nintedanib, mycophenolate mofetil (MMF), methotrexate (MTX) OR azathioprine, and corticosteroids
- Women of childbearing potential are eligible to participate if not pregnant or breastfeeding and either willing to use an acceptable contraceptive method or sexually abstinent
- Able to provide written informed consent and understand and comply with the requirements of the study
Exclusion Criteria:
- Has an airway obstruction per pulmonary function test (PFT) or clinically significant pulmonary arterial hypertension
- Has current clinical diagnosis of another inflammatory connective tissue disease
- Has any active infections, a serious infection within the past 3 months, or chronic bacterial infection
- Is a current smoker or smoking within 6 months of screening
- Has any concomitant medical conditions that, in the opinion of the investigator, might place them in unacceptable risk for participation in the study
- Meets the protocol criteria for important laboratory exclusion criteria
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Tulisokibart
Tulisokibart IV administered by IV infusion |
Tulisokibart administered at timepoints as directed by the protocol
다른 이름들:
CDx+ or CDx- |
|
위약 비교기: Placebo
Placebo administered by IV infusion |
Placebo CDx+ or CDx- |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants who Experience an Adverse Event (AE)
기간: Up to Week 50
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants who experience an AE will be reported. |
Up to Week 50
|
|
Number of Participants who Experience a Serious Adverse Event (SAE)
기간: Up to Week 50
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants who experience an SAE will be reported. |
Up to Week 50
|
|
Number of Participants who Discontinue due to an AE
기간: Up to Week 50
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants who discontinue due to an AE will be reported. |
Up to Week 50
|
|
Change from Baseline in the Annual Rate of Change in Forced Vital Capacity (FVC) at Week 50
기간: Baseline and up to Week 50
|
FVC, as measured in milliliters by spirometry, is the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. |
Baseline and up to Week 50
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in FVC at Week 50
기간: Baseline and Week 50
|
FVC, as measured in milliliters by spirometry, is the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. |
Baseline and Week 50
|
|
Change from Baseline in High-Resolution Computer Tomography (HRCT) Quantitative Interstitial Lung Disease - Whole Lung (QILD-WL) at Week 50
기간: Baseline and Week 50
|
QILD-WL will be measured as percent lung involvement using HRCT. |
Baseline and Week 50
|
|
Percentage of Participants with an Improvement in the Revised Composite Response Index in Systemic Sclerosis (CRISS) Score at Week 50
기간: Baseline and Week 50
|
The Revised CRISS is a two-step process designed to evaluate the likelihood of improvement in early SSc. The first step assesses worsening or incident cases of internal organ involvement (scleroderma renal crisis, pulmonary arterial hypertension, congestive heart failure, ILD, severe gastrointestinal dysmotility requiring parenteral or enteral nutrition, and digital ischemia requiring hospitalization, gangrene, or amputation). The second step assesses changes from baseline in five core set measures: modified Rodnan skin score (mRSS), percent predicted forced vital capacity (FVC%), health assessment questionnaire-disability index (HAQ-DI), patient (PGA), and physician (PhGA) global assessments. |
Baseline and Week 50
|
|
Change from Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 50
기간: Baseline and Week 50
|
HAQ is an instrument to assess physical function. It consists of 20 questions, covering eight types of activities. For each question, scores range from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty or with assistance; 3 = unable to do). HAQ Disability Index (HAQ-DI) score is the average of the highest score in each of the eight categories. |
Baseline and Week 50
|
|
Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Quality of Life (QoL) Outcome at Week 50
기간: Baseline and Week 50
|
The L-PF is a questionnaire designed to assess the quality of life of patients with pulmonary fibrosis. It contains 44 questions (items) split into two modules, 23 which assess symptoms (including shortness of breath, cough, and fatigue) and 21 which assess impacts to quality of life. Individual items are scored on a 5-point scale (0 = Not at All to 4 = Extremely). Overall scores range from 0 to 100 with higher scores indicating a greater impairment. |
Baseline and Week 50
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Prometheus Biosciences, Clinical Trials Call Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 7240-007
- PR200-104 (기타 식별자: PrometheusBio)
- 2021-005206-10 (EudraCT 번호)
- MK-7240-007 (기타 식별자: MSD)
- U1111-1309-6150 (레지스트리 식별자: UTN)
- 2023-509743-27-00 (레지스트리 식별자: EU CT)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .